v1
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy in First-Line Metastatic NSCLC: Five-Year Overall Survival Outcomes From the Phase 3 POSEIDON Trial
NobleIDNI7P40W81R76S00
Type:Journal Article
0 views
Embeddable Badge
[](https://nobleid.org/work/w1/20260526/806387A7)
ARK Inflections
Metadata Formats
Bibliometric Analysis
Impact metrics, research fronts, co-authorship networks →
Authors & Claims
Paper Authors
Solange Peters
Byoung Chul Cho
Alexander V. Luft
Jorge Alatorre-Alexander
Sarayut Lucien Geater
Konstantin Laktionov
Dmytro Trukhin
Sang-We Kim
Grygorii M. Ursol
Maen Hussein